The correlations of miR-582-3p expression and its interactions with lncRNA TUG1 with AKT/mTOR signaling and ovarian cancer outcomes suggest that the lncRNA TUG1/miR-582-3p/AKT/mTOR axis may be used as a novel prognostic biomarker and therapeutic target in OC. This evidence concerns the gene TUG1 and ovarian carcinoma.